Capital Management Corp VA Raises Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Capital Management Corp VA increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 3.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 352,566 shares of the company’s stock after buying an additional 10,605 shares during the period. Harmony Biosciences comprises approximately 1.9% of Capital Management Corp VA’s investment portfolio, making the stock its 25th biggest holding. Capital Management Corp VA owned about 0.61% of Harmony Biosciences worth $11,141,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of HRMY. GAMMA Investing LLC raised its position in shares of Harmony Biosciences by 222.9% in the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company’s stock worth $97,000 after acquiring an additional 2,022 shares in the last quarter. Strs Ohio bought a new position in Harmony Biosciences in the first quarter worth about $587,000. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Harmony Biosciences during the second quarter valued at about $1,478,000. CX Institutional boosted its holdings in shares of Harmony Biosciences by 166.8% in the 2nd quarter. CX Institutional now owns 207,783 shares of the company’s stock valued at $6,566,000 after buying an additional 129,916 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in shares of Harmony Biosciences in the 1st quarter worth approximately $6,035,000. Institutional investors own 86.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Mizuho cut their price target on shares of Harmony Biosciences from $50.00 to $35.00 and set an “outperform” rating on the stock in a report on Thursday, September 25th. Deutsche Bank Aktiengesellschaft dropped their target price on Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. Wall Street Zen upgraded Harmony Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday. Truist Financial began coverage on Harmony Biosciences in a research note on Monday, July 21st. They set a “buy” rating and a $48.00 price target on the stock. Finally, Needham & Company LLC cut their price objective on shares of Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating on the stock in a report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $46.11.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $26.84 on Wednesday. The stock has a market cap of $1.54 billion, a PE ratio of 8.66, a price-to-earnings-growth ratio of 0.32 and a beta of 0.79. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.95 and a 52-week high of $41.61. The business has a 50-day simple moving average of $32.78 and a 200-day simple moving average of $32.79. The company has a quick ratio of 3.80, a current ratio of 3.84 and a debt-to-equity ratio of 0.20.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.10). The firm had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The firm’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.05 EPS. Harmony Biosciences has set its FY 2025 guidance at EPS. On average, equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.